The safety profile and efficacy of Xiidra® vs. vehicle were studied in 2247 subjects diagnosed with Dry Eye Disease in four randomized,double-masked, 12-week trials.¹
Each of the four studies assessed the effect of Xiidra® vs. vehicle on both the signs and symptoms of Dry Eye Disease at baseline and weeks 2, 6, and 12. Assessment of signs was based on change from baseline in ICSS. ICSS was measured on a scale of 0 to 4 in increments of 0.5.¹
Ce site est réservé aux professionnels de la santé. Veuillez visiter le site Web à l’intention des patients. Mot de passe (numéro DIN de XIIDRAMD) : 02471027